BF.7: Strongest infection ability Omicron COVID variant

Reports from China indicate that BF.7 is more infectious than other Omicron subvariants, with a higher transmission rate (R0) of 10 to 18.6, compared to an average R0 of 5.08 for Omicron as a whole. BF.7 is also more resistant to neutralization by antibodies generated by vaccines or previous infection due to a mutation called R346T in its spike protein.

The symptoms of an infection with BF.7 are similar to those of other Omicron subvariants, including upper respiratory tract symptoms like fever, cough, and fatigue, as well as potentially gastrointestinal symptoms like vomiting and diarrhea. In those with weakened immune systems, exposure to BF.7 may result in more severe illness. Despite its presence in several countries, BF.7 does not seem to be spreading as rapidly elsewhere as it is in China, where it is causing significant difficulty in controlling the epidemic. The situation in China may be due to a low level of immunity in the population from previous infections or vaccination.

BF.7 has been detected in several other countries around the world, including the United States, the United Kingdom, and various European countries. While it has immune-evasive characteristics and has caused concern due to its rapid growth in China, it seems to remain fairly steady in other parts of the world.

For example, in the United States, it was estimated to account for only 5.7% of infections as of December 10, down from 6.6% the week prior. In the UK, the Health Security Agency identified BF.7 as a cause for concern in terms of growth and neutralization data in an October briefing, but a more recent briefing notes that it has been de-escalated due to reduced incidence and low growth rates in the country.

Overall, while the emergence of new variants like BF.7 is concerning, vaccination remains the best way to combat COVID-19.

In conclusion, the COVID-19 virus has continued to evolve since its emergence three years ago, acquiring genetic mutations at a faster rate than expected. The emergence of new variants like BF.7 is a cause for concern, but vaccination remains the most effective way to combat the virus.

Overall, it is important to continue following public health guidelines and getting vaccinated in order to protect ourselves and our communities from the spread of COVID-19.


  1. Omicron BF.7, major strain causing latest outbreak in Beijing, has strong infectious ability: medical expert. [Cited 21st December 2022]. Available at:
  2. Liu Y, Rocklöv J. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med. 2022 May 31;29(3):taac037. doi: 10.1093/jtm/taac037. PMID: 35262737; PMCID: PMC8992231.
  3. Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, Bondzie EA, Powers O, Surve N, Hall K, Barouch DH. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22. PMID: 35731894; PMCID: PMC9258748.
  4. COVID Data Tracker. [Cited 21st December 2022]. Available at:
Share it with

Similar Articles

Data Privacy Notice

This Privacy Notice shall be read in conjunction with the Privacy Policy to the extent this Notice does not mention or specify the particulars that should have been mentioned or specified relating to the Notice in pursuance of the provisions of the Data Protection Laws as applicable.

On having accessed or visited this Platform you the Noticee hereby voluntarily consent to and take notice of the fact that the personal data, by which or in relation whereto you the concerned Noticee is identifiable, shall be retained, stored, used, and may be processed by the Company for the purpose and in the manner, though legal, found suitable to it for commercial and/or some other reasons. The detailed specificity whereof may be found in the Privacy Policy. The consent provided herein may be withdrawn anytime by you, the Noticee, at its own volition by removing your profile or by writing to us at

As a Noticee, you shall have the right to grievance redressal, in relation to your consent or our use of your personal data, which you may address by writing to us at Should you, the Noticee, thereafter remain unsatisfied or dissatisfied with the resolution provided by us, you, the Noticee, may approach the concerned regulatory authority for the redressal of your grievance.

Thanks for exploring our medical content.

Create your free account or log in to continue reading.

Data Privacy Notice

By using this platform, you consent to our use of your personal data as detailed in our Privacy Policy, and acknowledge that we use cookies to improve your browsing experience